Drugs / PF-07258669
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07086664 | Aug 2025 → Jan 2026 | — | Pfizer | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT06706869 | Dec 2024 → Feb 2025 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT05113940 | Nov 2021 → Jul 2023 | — | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT04628793 | Mar → Aug 2021 | — | Pfizer | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-07258669 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07086664 ↗ |
| Route | Oral | “PF-07258669 will be prepared as an oral solution and/or suspension given in escalating single doses to be determined” NCT04628793 ↗ |